ModifiedCapital BluecrossPolicy MP 2.390

Adjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia

This policy governs the coverage stance for adjunctive diagnostic and risk-classification tests (WATS3D, EsoCheck, EsoGuard, TissueCypher, BarreGen) used for screening, surveillance, or risk stratification of Barrett esophagus and esophageal dysplasia for Capital BlueCross members.

Policy Summary

PayerCapital Bluecross

PolicyAdjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia

Policy CodePolicy MP 2.390

Change TypeMajor review — investigational determinations added for EsoCheck/Esoguard, TissueCypher, BarreGenCategory III codes 0108U and 0114U added as investigational

Effective DateSep 1, 2025

Next Review DateJan 23, 2025

Key ActionVerify member benefits and follow investigational coverage rules; expect claims for listed adjunctive tests and new Category III codes may be denied.

SourceLink

POLICY UPDATE CHANGES

EsoCheck and Esoguard are considered investigational for the screening and surveillance of Barrett esophagus and esophageal dysplasia.

TissueCypher is considered investigational for assessing the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in individuals with Barrett esophagus.

BarreGen is considered investigational for the risk stratification of Barrett esophagus and esophageal dysplasia.

Added codes 0108U and 0114U as investigational.

Policy title changed to 'Adjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia.'

5technologies considered investigational

3new investigational test statements added

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

2new Category III codes added

5.6%estimated US prevalence of BE

0.2–0.5%/yrprogression risk (nondysplastic BE)

Coverage Criteria — Adjunctive Techniques for Barrett Esophagus

Investigational / Not covered

Adjunctive tests for screening, surveillance, or risk classification are considered investigational for all indications unless specific evidence demonstrating clinical utility with improved net health outcomes is provided.

WATS3D (wide-area transepithelial sampling with three-dimensional computer-assisted analysis) is considered investigational for all indications, including screening and surveillance of Barrett esophagus and esophageal dysplasia.

See policy statement and rationale (chunks 1, 8, 10).

EsoCheck / EsoGuard: EsoCheck and EsoGuard (non‑endoscopic esophageal sampling/DNA‑based assays) are considered investigational for the screening and surveillance of Barrett esophagus and esophageal dysplasia.

See policy statement and diagnostic accuracy/utility discussion (chunks 1, 11).

TissueCypher (tissue‑systems pathology assay) is considered investigational for assessing risk of progression to high‑grade dysplasia or esophageal adenocarcinoma in individuals with Barrett esophagus.

See policy statement and clinical validity/utility discussion (chunks 1, 12).

BarreGen (topographic genotyping/esophageal cancer risk classifier) is considered investigational for assessing risk of progression to high‑grade dysplasia or esophageal adenocarcinoma in individuals with Barrett esophagus.

See policy statement; no direct studies identified (chunks 1, 13).

Investigational / Not Covered Techniques

Adjunctive techniques newly specified as investigational in this policy update:

Newly added investigational techniques: EsoCheck and EsoGuard are investigational for the screening and surveillance of Barrett esophagus and esophageal dysplasia; TissueCypher is investigational for assessing progression risk to high‑grade dysplasia or esophageal adenocarcinoma; BarreGen is investigational for risk stratification of Barrett esophagus and esophageal dysplasia.

Statements added in Major Review (chunk 29).

WATS3D, EsoCheck, EsoGuard, TissueCypher, and BarreGen are considered investigational for all indications related to Barrett esophagus and esophageal dysplasia and are therefore not covered. This includes use for screening, surveillance, or risk-classification purposes as described in the policy statements and coding guidance (see listed investigational procedure codes).

Specifically, the policy lists these adjunctive technologies as investigational and identifies associated procedure codes that may be denied when billed for these services in the evaluation or management of Barrett esophagus (see Coding section for affected CPT/CPT Category III and pathology codes).

This policy update adds specific investigational determinations for three adjunctive technologies: EsoCheck / EsoGuard are investigational for screening and surveillance of Barrett esophagus and esophageal dysplasia; TissueCypher is investigational for assessing progression risk to high-grade dysplasia or esophageal adenocarcinoma; and BarreGen is investigational for risk stratification of Barrett esophagus and esophageal dysplasia.

Because these technologies are designated investigational in this policy, they are excluded from coverage under the investigational/not-covered classification and claims for these procedures may be denied in accordance with program and product-specific benefit terms.

The policy conclusion that these adjunctive tests remain investigational is driven by the absence of direct evidence demonstrating clinical utility — i.e., studies showing that use of the tests to guide management leads to improved net health outcomes such as reduced progression to advanced neoplasia, improved survival, or better quality of life. Available data primarily address diagnostic yield, risk stratification, or physician decision impact but do not provide longitudinal outcomes showing patient benefit.

Examples in the evidence base include meta-analyses and diagnostic-yield studies for WATS3D, observational diagnostic accuracy studies for EsoCheck/EsoGuard, and clinical validity and physician-impact reports for TissueCypher; none provide direct, long-term outcome data that confirm management changes prompted by these tests improve clinical endpoints rather than potentially leading to overdiagnosis or overtreatment. For BarreGen, no clinical studies demonstrating impact on patient outcomes were identified.

Coding — Procedure and Diagnosis Codes

Not covered procedure codesCPTNot Covered

88104	Procedure Codes (listed as considered investigational/not covered mapping to multiple pathology codes)
88305	Surgical pathology, gross and microscopic examination
88312	Special staining, each
88361	Morphometric analysis or computer-assisted quantification
0108U	Molecular pathology procedure (listed)
0114U	Molecular pathology procedure (listed)

Relevant diagnosis codes listedICD-10

K22.70	Barrett's esophagus without dysplasia
K22.710	Barrett's esophagus with low grade dysplasia
K22.711	Barrett's esophagus with high grade dysplasia
K22.719	Barrett's esophagus with dysplasia, unspecified
K22.89	Other specified disease of esophagus
K22.9	Disease of esophagus, unspecified

Investigational CPT/HCPCS Category III CodesCPTNot Covered

0108U	Category III code added and listed as investigational in policy
0114U	Category III code added and listed as investigational in policy

Provider Actions, Billing, and Prior Authorization

Prior Authorization

Prior authorization guidance

Providers should follow product/program variations and FEP guidance when applicable. This policy applies only to certain Capital Blue Cross programs and products and may be subject to benefit variations; check FEP members against the FEP Medical Policy Manual.

Applicable programs and products may vary — verify program applicability before proceeding.

Prior Authorization

Investigational codes added

Category III CPT codes 0108U and 0114U have been added and are considered investigational under this policy. These investigational codes are subject to prior authorization requirements and may be denied if submitted for coverage.

Affected codes: 0108U, 0114U
Follow prior authorization requirements for investigational services.

Background — Clinical Context

Barrett esophagus (BE) is a condition in which the normal squamous epithelium of the distal esophagus is replaced by intestinal-type columnar epithelium (intestinal metaplasia), a change confirmed by biopsy and histology and recognized as a precursor to esophageal adenocarcinoma.

BE prevalence in the U.S. has been estimated at approximately 5.6%, and progression risk varies by dysplasia grade (nondysplastic BE ≈ 0.2–0.5% per year; low-grade dysplasia ~0.7% per year; high-grade dysplasia ≈ 7% per year), which underlies the need for stratified surveillance and management strategies.

Definitions and Test Descriptions

Barrett esophagus (BE) — definition and clinical notes

DefinitionBarrett esophagus (BE) is replacement of the distal esophageal squamous epithelium by specialized intestinal-type columnar epithelium (intestinal metaplasia) confirmed by biopsy and microscopic identification.

Anatomic/visual featuresOccurs in the distal esophagus, may be focal or circumferential, and is visualized on endoscopy as mucosa with a different color than background squamous mucosa.

Confirmation requirementDiagnosis requires endoscopic biopsy of columnar epithelium and histologic identification of intestinal metaplasia.

EpidemiologyEstimated U.S. prevalence approximately 5.6%.

Risk factorsAssociated with GERD, male sex, central obesity, and age >50 years; GERD diagnosis associated with 10%–15% risk of BE.

Policy Summary

PayerCapital Bluecross

PolicyAdjunctive Techniques for Screening, Surveillance, and Risk Classification of Barrett Esophagus and Esophageal Dysplasia

Policy CodePolicy MP 2.390

Change TypeMajor review — investigational determinations added for EsoCheck/Esoguard, TissueCypher, BarreGenCategory III codes 0108U and 0114U added as investigational

Effective DateSep 1, 2025

Next Review DateJan 23, 2025

Key ActionVerify member benefits and follow investigational coverage rules; expect claims for listed adjunctive tests and new Category III codes may be denied.

SourceLink

On This Page

Denial Risk

Investigational — not covered

WATS3D, EsoCheck, Esoguard, TissueCypher, and BarreGen are considered investigational and are not covered for screening, surveillance, or risk assessment of Barrett esophagus and esophageal dysplasia.

Examples of investigational services that are not covered: WATS3D, EsoCheck, EsoGuard, TissueCypher, BarreGen

Note

Benefit verification

Verify member benefits and eligibility prior to providing services. Medical policy determinations do not guarantee coverage or payment — final payment is subject to the member's benefit program, eligibility on the date of service, and that services are medically necessary and appropriate.

Confirm member benefit plan, eligibility, and any program-specific variations before scheduling or submitting claims.

Documentation Required

Documentation note

If submitting investigational tests or codes for clinical consideration, document the clinical rationale and supporting evidence in the medical record. Include indication, prior testing, and clinical justification for ordering the investigational service to support any potential medical review.

Document indication, prior diagnostics, and clinical rationale in the medical record when requesting coverage consideration for investigational services.
Maintain supporting clinical records to accompany prior authorization or appeals if pursued.

Denial Risk

Investigational procedure denial risk

Claims for EsoCheck/Esoguard, TissueCypher, BarreGen, and WATS3D may be denied as investigational per this policy; expect denials for these services unless benefit terms explicitly provide coverage.

Services at risk for denial: EsoCheck, Esoguard, TissueCypher, BarreGen, WATS3D
Check coding and benefit rules prior to submission.

WATS3D — definition and description

DefinitionWide-area transepithelial sampling with three-dimensional computer-assisted analysis (WATS3D) is an adjunctive sampling technique combining broad-area brush sampling with 3D computer-assisted cytologic analysis to detect intestinal metaplasia and dysplasia.

PurposeStudied as an adjunct to standard endoscopic biopsy to improve detection of Barrett's esophagus and esophageal dysplasia.

Evidence baseEvaluated in randomized, prospective, systematic review, and cost-effectiveness studies cited in the policy literature (see CDx Diagnostics, randomized trial, and meta-analyses).

TissueCypher — tissue‑systems pathology assay

DefinitionTissueCypher is a tissue-systems pathology assay intended to predict risk of progression in patients with Barrett's esophagus using automated, multiplexed tissue analysis.

Intended useProposed to risk-stratify patients with nondysplastic or low-grade dysplasia to predict progression to high-grade dysplasia or esophageal adenocarcinoma.

Supporting studiesIndependent validations and studies of clinical impact, prognostic performance, and potential to influence management are cited (Davison et al., Frei et al., Khoshiwal et al.).

EsoCheck / Esoguard — non‑endoscopic esophageal sampling and DNA assays

DefinitionEsoCheck/Esoguard are nonendoscopic esophageal sampling devices with DNA-based assays marketed for screening or triage to identify Barrett's esophagus.

ModalityNonendoscopic brush or capsule-based sampling of esophageal cells followed by molecular/DNA testing intended to screen or triage for endoscopy.

Evidence notesReal-world and observational registry data and recent nonendoscopic screening studies are cited in the policy (Greer et al.; Englehardt et al.; registry/interim reports).

BarreGen — esophageal cancer risk classifier

DefinitionBarreGen is an esophageal cancer risk classifier marketed by Interpace Diagnostics for risk stratification of Barrett's esophagus.

Intended roleUsed as a molecular/genotypic test to inform risk of progression in patients with Barrett's esophagus and esophageal dysplasia.

Supporting informationManufacturer information and validation studies are cited in the policy references (Interpace Diagnostics product information).